Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05236764 · ClinicalTrials.gov registry record · NA
Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion
A NA study of Myelodysplastic Syndromes and Chronic Myeloid Leukemia, sponsored by Baylor College of Medicine.
- Active
- Registry status
- NA
- Development phase
- 3
- Enrollment target
- 2
- Study locations
NCT05236764 is a NA study of Myelodysplastic Syndromes and Chronic Myeloid Leukemia that is active but no longer recruiting, run by Baylor College of Medicine. The registered enrollment target is 3 participants, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT05236764, a NA study of Myelodysplastic Syndromes and Chronic Myeloid Leukemia, is active but no longer recruiting, sponsored by Baylor College of Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 3 participants
- Enrollment target
- 2
- Study locations
Study Summary
Patients with medical conditions requiring allogeneic hematopoietic cell transplantation (allo-HCT) are at risk of developing a condition called graft versus host disease (GvHD) which carries a high morbidity and mortality. This is a phase I/II study that will test the safety and efficacy of hematopoietic cell transplantation (HCT) with ex-vivo T cell receptor Alpha/Beta+ and CD19 depletion to treat patients' underlying condition. This process is expected to substantially decrease the risk of GvHD thus allowing for the elimination of immunosuppressive therapy post-transplant. The study will use blood stem/progenitor cells collected from the peripheral blood of parent or other half-matched (haploidentical) family member donor. The procedure will be performed using CliniMACS® TCRα/β-Biotin System which is considered investigational.
Conditions Studied
Interventions
- DEVICE CliniMACS
Study Locations (2)
Texas
- Houston Methodist Hospital - Houston
- Texas Children's Hospital - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2023-12-06 |
| Est. Completion | 2026-05-23 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05236764
The ClinicalTrials.gov registry entry for NCT05236764 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (99% lower). The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Myelodysplastic Syndromes appearing as the primary indexed condition, and to 1 intervention - of which CliniMACS is the first listed.
NCT05236764 reports 2 study locations spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT05236764 about?
NCT05236764 is a clinical study titled "Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion". Patients with medical conditions requiring allogeneic hematopoietic cell transplantation (allo-HCT) are at risk of developing a condition called graft versus host disease (GvHD) which carries a high morbidity and mortality. This is a phase I/II study that will test the safety and efficacy of hematop...
What is the current status of trial NCT05236764?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 3 participants. The study started on 2023-12-06. Estimated completion is 2026-05-23.
What conditions does trial NCT05236764 study?
This clinical trial studies the following conditions: Myelodysplastic Syndromes, Chronic Myeloid Leukemia, Hemoglobinopathies, Severe Aplastic Anemia, Acute Myeloid Leukemia in Remission.
What interventions are being tested in trial NCT05236764?
The interventions under investigation include: CliniMACS (DEVICE).
Who is sponsoring clinical trial NCT05236764?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05236764 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelodysplastic Syndromes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Telehealth Advance Care Planning Intervention
RECRUITING · NA
-
Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS
RECRUITING · NA
-
HEME Home Transfusion Program
RECRUITING · NA
-
Home Blood Transfusions
RECRUITING · NA
-
Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in MDS
RECRUITING · NA
-
Mosaic Trial for Stem Cell Transplant Recipients
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.